Equities

Repare Therapeutics Inc

RPTX:NSQ

Repare Therapeutics Inc

Actions
  • Price (USD)2.97
  • Today's Change0.13 / 4.58%
  • Shares traded114.77k
  • 1 Year change-37.61%
  • Beta0.6840
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments224344342
Total Receivables, Net154.323.23
Total Inventory------
Prepaid expenses4.755.726.31
Other current assets, total------
Total current assets244354351
Property, plant & equipment, net7.549.6013
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term2.28----
Other long term assets0.400.500.59
Total assets254364369
LIABILITIES
Accounts payable2.400.462.30
Accrued expenses262420
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total105513
Total current liabilities397935
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total2.745.9445
Total liabilities428580
SHAREHOLDERS EQUITY
Common stock483482481
Additional paid-in capital623718
Retained earnings (accumulated deficit)(333)(239)(210)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.03(0.43)--
Total equity212280288
Total liabilities & shareholders' equity254364369
Total common shares outstanding424242
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.